Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1090

Sort by

Sort Order Select

Journal Articles

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, Norifumi Sugawara, MD, PhD, Shinri Miyajima, MD, Kazuki Kiyohara, MD, Maki Nishiya, MD PhD, Tadashi Shimoyama, MD PhD, Yuka Takemasa-Fujisawa, MD PhD, Ryosei Sasaki, MD PhD, Wataru Izumita, MD, Yasuhiko Tsukushi, MD, PhD, Akihiro Otsu, MD, PhD, Takahiro Mine, MD, Takeshi Sugawara, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, PhD, Ichiro Hanamura, MD PhD, Shugo Kowata, MD, PhD, Shigeki Ito, MD, PhD

Blood (2019) 134 (Supplement_1): 4865.

https://doi.org/10.1182/blood-2019-131305

Published: 2019

Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Blood (2019) 134 (Supplement_1): 845.

https://doi.org/10.1182/blood-2019-122802

Published: 2019

Journal Articles

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Blood (2019) 134 (Supplement_1): 1709.

https://doi.org/10.1182/blood-2019-122032

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao

Blood (2019) 134 (Supplement_1): 3495.

https://doi.org/10.1182/blood-2019-124878

Published: 2019

Journal Articles

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Yu Wang, Lan-Ping Xu, Kaiyan Liu, MD PhD, Xiao-Hui Zhang, Chen-hua Yan, Xiao-Jun Huang, MD

Blood (2019) 134 (Supplement_1): 4607.

https://doi.org/10.1182/blood-2019-124046

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Pierre-Edouard Debureaux, Flore Sicre de Fontbrune, Carmem M. S. Bonfim, MD, Jean-Hugues Dalle, MD PhD, Nimrod Buchbinder, MD, Yves Bertrand, MD, Cecile Renard, MD, Edouard Forcade, MD, Juliana Fernandes, MD, Alexis Talbot, MD, Ricardo Pasquini, MD, Jean Soulier, MD PhD, Thierry Leblanc, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2498.

https://doi.org/10.1182/blood-2019-122007

Published: 2019

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Alejandro Garcia-Horton, MDFRCPC, Yashoda Valliere, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 5425.

https://doi.org/10.1182/blood-2019-126806

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Masayuki Shiseki, MD PhD, Mayuko Ishii, Mari Ohwashi, Kentaro Yoshinaga, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 4258.

https://doi.org/10.1182/blood-2019-124738

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

Patrizia Chiusolo, Andrea Bacigalupo, MD, Simona Sica, MD, Sabrina Giammarco, MD PhD, Elisabetta Metafuni, Federica Sora, MD, Luca Laurenti, MD, Francesco Autore, MD, Idanna Innocenti, MD PhD, Silvia Bellesi, Gina Zini, MD PhD, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, MD

Blood (2019) 134 (Supplement_1): 3332.

https://doi.org/10.1182/blood-2019-130849

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Mitoxantrone in Pediatric Refractory and Relapse Acute Myeloid Leukemia and MDS-Raebt

Liyan Fan, MD, Aili Chen, MD, Yixin Hu, MD, Peifang Xiao, MD, Jun Lu, MD, Jie Li, MD, Hailong He, MD, Yi Wang, MD, Shaoyan Hu, MD PhD

Blood (2018) 132 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2018-99-117850

Published: 2018

NARROW

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Impact of Cytoreductive Therapy and Depth of Response before Allogeneic Transplantation for Advanced Myelodysplastic Syndrome

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Mitoxantrone in Pediatric Refractory and Relapse Acute Myeloid Leukemia and MDS-Raebt

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only